Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors significantly prolong the progression-free survival of patients with non-squamous non-small cell lung cancer (NSCLC). However, most patients develop tumor regrowth and their prognosis remains poor. A new treatment strategy for N...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, Takayasu, Nakaya, Aya, Yokoi, Takashi, Niki, Maiko, Kibata, Kayoko, Takeyasu, Yuki, Torii, Yoshitaro, Katashiba, Yuichi, Ogata, Makoto, Miyara, Takayuki, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511889/
https://www.ncbi.nlm.nih.gov/pubmed/28740574
http://dx.doi.org/10.18632/genesandcancer.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511889/
https://www.ncbi.nlm.nih.gov/pubmed/28740574
http://dx.doi.org/10.18632/genesandcancer.145

Ejemplares similares